Skip to main content


Fig. 3 | Molecular Cancer

Fig. 3

From: Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges

Fig. 3

RTK signaling in drug resistance. a Conventional chemotherapeutic agents reduce the cancer progression through the inhibition of MAPK/PI3K/Akt signaling axis. Amplification and overexpression of RTKs including EGFR, HER2 and PDGFR reinforce the activation of PI3K/Akt/YB-1/RTK axis to maintain drug resistance; increases the kinase activity and thereby leading to cancer progression, drug efflux and cancer stemness. b Cancer cells exhibit resistance to RTK therapy due to disruption of interaction between drug and receptor or activation of alternate RTK signaling

Back to article page